APhA, oldest U.S. pharmacy group, honors Kadlec with Schaefer Award
WASHINGTON The American Pharmacists Association has bestowed one of its highest honors, the 2010 Hugo H. Schaefer Award, on Gary Kadlec, president and CEO of Hospice Pharmacia and ExcelleRx.
APhA will present the honor at its Annual Meeting and Exposition in Washington, March 12-15. The Schaefer Award was established in 1964 in honor of the group’s longtime treasurer, and recognizes outstanding voluntary contributions to the organization, the profession and society,” according to APhA.
Kadlec’s pharmacy career dates back to the early 1970s, when he was first an intern and then pharmacist at St. Joseph Mercy Hospital in Pontiac, Mich. From 1976 to 1995 he was owner and president of Specialized Pharmacy Services Inc., purchased in 1995 by Omnicare Inc., a top provider of pharmaceutical care for seniors.
At Omnicare, Kadlec rose to senior regional VP before becoming the top executive at Hospice Pharmacia and excelleRx, an Omnicare division. “Under Kadlec’s leadership, excelleRx continues to develop into a state-of-the-art medication Mmanagement service… providing cutting-edge pharmacy practice,” APhA reported.
Kadlec has also been active within the Academy of Managed Care Pharmacy, the American Society of Consultant Pharmacists and the American Society of Health System Pharmacists. He also is a past president and past chairman of the Michigan Pharmacists Association [MPA], and has been tapped for numerous honors. Among them: MPA Pharmacist of the Year, Merck’s “Outstanding Achievement in the Profession of Pharmacy,” and a Distinguished Achievement Award in Administrative Practice from APhA’s Academy of Pharmacy Practice and Management.
“Gary continues to put his considerable talents and energy toward enhancing APhA and the profession,” noted the organization, founded in 1852. “As a third-generation pharmacist, he has been a strong mentor to the many pharmacists who have worked with him.”
FDA approves Menveo
CAMBRIDGE, Mass. Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the Swiss drug maker’s vaccines division announced Monday.
The FDA approved Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197) to prevent meningococcal disease caused by Neisseria meningitidis bacteria.
The disease infects more than 500,000 people each year, killing as many as 1-in-7 who contract it; it is often fatal within 48 hours. About one-in-five who survive have serious side effects, including limb amputations, learning disabilities, seizures and paralysis.
“The FDA approval of Menveo is an important milestone for adolescent immunization in the United States,” Novartis vaccines division head Andrin Oswald said in a statement. “According to CDC estimates, approximately 16 million adolescents between the ages of 11 and 18 are at risk and remain unprotected against meningococcal disease.”
Watson CEO to serve as GPhA chairman
NAPLES, Fla. Watson Pharmaceuticals president and CEO Paul Bisaro will serve as the Generic Pharmaceutical Association’s chairman for 2010-2011, GPhA announced.
Bisaro has led Watson since 2007, after a stint as president and CEO of Barr Labs that began in 1999. He has served on GPhA’s board of directors since 2008, most recently as vice chairman.
“Paul will provide us with a steady hand as GPhA next navigates the often turbulent issues of health reform and the nation’s economic recovery,” GPhA president and CEO Kathleen Jaeger said. “GPhA looks forward to working with him, our board of directors and executive committee in what will be a challenging year.”
The organization also elected Mylan Pharmaceutical president Tony Mauro as vice chairman, New Chemic senior consultant Rosendo Ferran as secretary-treasurer. Nycomed U.S. CEO Paul McGarty, Teva North America president and CEO William Marth, Sandoz president and CEO Christine Mundkur and Zydus Pharmaceuticals president and CEO Joe Renner will serve as at-large members on the board’s executive committee.